(5Z)-7-[(1R,2R,3R,5S)-3,5-二羟基-2-[(1E,3S)-3-羟基-5-[3-(三氟甲基)苯基]-1-戊烯-1-基]环戊基]-5-庚烯酸 | 221246-34-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (5Z)-7-[(1R,2R,3R,5S)-3,5-二羟基-2-[(1E,3S)-3-羟基-5-[3-(三氟甲基)苯基]-1-戊烯-1-基]环戊基]-5-庚烯酸
• 英文名称: 17-(3-trifluoromethylphenyl)-17-trinor prostaglandin F_2α
• 英文别名: (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-[3-(trifluoromethyl)phenyl]pent-1-enyl]cyclopentyl]hept-5-enoic acid
• CAS: 221246-34-0
• 化学式: C₂₄H₃₁F₃O₅
• 分子量: 456.502
• InChiKey: CMLNDCUXASGBMQ-NQUQXYBYSA-N

物化性质

• 沸点：
  593.0±50.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：30mg/mL； DMSO：25mg/mL；乙醇：50mg/mL； PBS（pH 7.2）：1 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (5Z)-7-[(1R,2R,3R,5S)-3,5-二羟基-2-[(1E,3S)-3-羟基-5-[3-(三氟甲基)苯基]-1-戊烯-1-基]环戊基]-5-庚烯酸 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 13,14-dihydro-17-((3-trifluoromethyl)phenyl)-17-trinor prostaglandin F_1α
  参考文献：
  名称：

  Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

  摘要：

  The in vitro evaluation of a series of saturated prostaglandins revealed that compounds with omega chain aromatic rings retain nanomolar potency for the human prostaglandin F receptor (hFP receptor), exemplified by compound 8. In contrast, the double bonds are required for activity in the series with an acyclic omega chain as in PGF(2 alpha). (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00273-0
• 作为产物：
  描述：

  3-(3-三氟甲基苯基)丙酸 在 甲醇 、 lithium aluminium tetrahydride 、 正丁基锂 、 (-)-(S)-BINAL-H 、 sodium hexamethyldisilazane 、 二异丁基氢化铝 、 potassium carbonate 、 对甲苯磺酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 为溶剂， 生成 (5Z)-7-[(1R,2R,3R,5S)-3,5-二羟基-2-[(1E,3S)-3-羟基-5-[3-(三氟甲基)苯基]-1-戊烯-1-基]环戊基]-5-庚烯酸
  参考文献：
  名称：

  Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

  摘要：

  The in vitro evaluation of a series of saturated prostaglandins revealed that compounds with omega chain aromatic rings retain nanomolar potency for the human prostaglandin F receptor (hFP receptor), exemplified by compound 8. In contrast, the double bonds are required for activity in the series with an acyclic omega chain as in PGF(2 alpha). (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(00)00273-0

文献信息

• Combination therapy
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US11020385B2

  公开（公告）日：2021-06-01

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼内压的化合物和组合物。组合物可包括异喹啉化合物和前列腺素或前列腺素类似物。本文所述的化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的化合物，以及异喹啉化合物和前列腺素游离酸共同形成盐的化合物。
• Poly(ketals) and related compositions and methods
  申请人：Children's Medical Center Corporation

  公开号：US11071714B2

  公开（公告）日：2021-07-27

  Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one or more ketal, monothioketal, and/or thioketal bonds and a precursor of a pharmaceutically active agent. The precursor of the pharmaceutically active agent may be located in the backbone or may be a pendant group. The polymer may degrade in certain environments (e.g., aqueous environments, acidic environments, in vivo, etc.) to produce the pharmaceutically active agent and other biocompatible degradation products, such as certain ketones, alcohols, and/or thiols. Regardless of the location of the precursor of the pharmaceutically active agent in the repeat unit(s), the polymer may have a prolonged degradation time and/or release of the pharmaceutically active agent in certain environments. Various compositions, described herein, may be particularly well suited for applications requiring extended release of pharmaceutically active agents, such as the treatment of ophthalmic disorders.

  本发明提供了由包含一个或多个酮键、单硫酮键和/或硫酮键的聚合物组成的组合物以及相关方法和试剂盒。在某些实施方案中，聚合物可包含一个或多个由一个或多个酮键、单硫酮键和/或硫酮键组成的重复单元和一种药用活性剂的前体。药用活性剂的前体可以位于骨架中，也可以是一个悬挂基团。聚合物可在特定环境（如水环境、酸性环境、体内等）中降解，产生药用活性剂和其他生物相容性降解产物，如某些酮、醇和/或硫醇。无论药用活性剂前体在重复单元中的位置如何，聚合物在某些环境中都可能会延长降解时间和/或释放药用活性剂。本文所述的各种组合物可能特别适用于需要延长药用活性剂释放时间的应用，如眼科疾病的治疗。
• Compositions for treating glaucoma or reducing intraocular pressure
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US11185538B2

  公开（公告）日：2021-11-30

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼内压的化合物和组合物。 组合物可包括异喹啉化合物和前列腺素或前列腺素类似物。 本文所述的化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的化合物，以及异喹啉化合物和前列腺素游离酸共同形成盐的化合物。
• COMBINATION THERAPY
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20200129498A1

  公开（公告）日：2020-04-30

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
• METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT
  申请人：Topokine Therapeutics, Inc.

  公开号：US20210213032A1

  公开（公告）日：2021-07-15

  Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use.